Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 6884869 Pentapeptide compounds and uses related thereto

Patent 6884869 was granted and assigned to Seagen on April, 2005 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Seagen
Seagen
0
Date Filed
November 1, 2001
0
Date of Patent
April 26, 2005
0
Patent Application Number
10001191
0
Patent Citations Received
‌
US Patent 12134610 Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
0
‌
US Patent 12064483 Nucleic acid-polypeptide compositions and methods of inducing exon skipping
0
‌
US Patent 12071485 Compositions and methods of treating facioscapulohumeral muscular dystrophy
0
‌
US Patent 12071621 Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
0
‌
US Patent 12104156 Compositions and methods of treating facioscapulohumeral muscular dystrophy
0
‌
US Patent 12129309 Heterodimeric antibodies that bind CD3 and CD38
0
‌
US Patent 11834510 Anti-transferrin receptor antibodies and uses thereof
0
‌
US Patent 11840579 Bispecific antibodies that bind to CD38 and CD3
0
‌
US Patent 11859012 Heterodimeric antibodies that bind CD3 and GPC3
0
‌
US Patent 11866496 Humanized anti-CD79B antibodies and immunoconjugates and methods of use
0
•••
Patent Inventor Names
Brian E. Toki
0
Peter D. Senter
0
Svetlana Doronina
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
6884869
0
Patent Primary Examiner
‌
Jon Weber
0

Find more entities like US Patent 6884869 Pentapeptide compounds and uses related thereto

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.